The presentation will commence with a brief overview of lipid screening in childhood and recognition of lipid profiles.
The focus will then be on the role of lipid lowering therapy for children and adolescents, to prevent cardiovascular disease in later life. The monogenic disorders familial hypercholesterolaemia (FH) and familial chylomicronaemia syndrome (FCS) will serve as models to understand the approach to managing severe hypercholesterolaemia and severe hypertriglyceridaemia in childhood.
Current and emerging pharmacological therapies to reduce total and low-density lipoprotein-cholesterol (LDL-C) and triglycerides (TG) will be discussed.
The presentation will end by considering the options for children and young people with obesity and abnormal lipid profiles.